11/7
11:14 am
kros
Keros Therapeutics, Inc. (NASDAQ: KROS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $84.00 price target on the stock.
Low
Report
Keros Therapeutics, Inc. (NASDAQ: KROS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $84.00 price target on the stock.
11/7
11:14 am
kros
Keros Therapeutics, Inc. (NASDAQ: KROS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $84.00 price target on the stock.
Low
Report
Keros Therapeutics, Inc. (NASDAQ: KROS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $84.00 price target on the stock.
11/7
08:36 am
kros
Keros Therapeutics, Inc. (NASDAQ: KROS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.
Low
Report
Keros Therapeutics, Inc. (NASDAQ: KROS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.
11/6
06:33 am
kros
Keros Therapeutics, Inc. (NASDAQ: KROS) was upgraded by analysts at Wedbush to a "strong-buy" rating.
Medium
Report
Keros Therapeutics, Inc. (NASDAQ: KROS) was upgraded by analysts at Wedbush to a "strong-buy" rating.
11/6
06:33 am
kros
Keros Therapeutics, Inc. (NASDAQ: KROS) was upgraded by analysts at Wedbush to a "strong-buy" rating.
Medium
Report
Keros Therapeutics, Inc. (NASDAQ: KROS) was upgraded by analysts at Wedbush to a "strong-buy" rating.
11/5
12:12 pm
kros
Keros Therapeutics initiated with bullish view at Jefferies
Low
Report
Keros Therapeutics initiated with bullish view at Jefferies
11/5
12:12 pm
kros
Keros Therapeutics initiated with bullish view at Jefferies
Low
Report
Keros Therapeutics initiated with bullish view at Jefferies
10/24
02:00 pm
kros
Rating for KROS
Low
Report
Rating for KROS
10/24
07:16 am
kros
Keros Therapeutics, Inc. (NASDAQ: KROS) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
Low
Report
Keros Therapeutics, Inc. (NASDAQ: KROS) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
10/24
06:12 am
kros
Keros Therapeutics initiated with bullish view at Cantor Fitzgerald
Low
Report
Keros Therapeutics initiated with bullish view at Cantor Fitzgerald
10/16
10:35 am
kros
Rating for KROS
Low
Report
Rating for KROS
10/16
10:35 am
kros
Rating for KROS
Low
Report
Rating for KROS
10/16
08:44 am
kros
Keros Therapeutics, Inc. (NASDAQ: KROS) is now covered by analysts at Scotiabank. They set a "sector outperform" rating on the stock.
Low
Report
Keros Therapeutics, Inc. (NASDAQ: KROS) is now covered by analysts at Scotiabank. They set a "sector outperform" rating on the stock.
10/16
08:44 am
kros
Keros Therapeutics, Inc. (NASDAQ: KROS) is now covered by analysts at Scotiabank. They set a "sector outperform" rating on the stock.
Low
Report
Keros Therapeutics, Inc. (NASDAQ: KROS) is now covered by analysts at Scotiabank. They set a "sector outperform" rating on the stock.
9/23
07:59 am
kros
Keros Therapeutics, Inc. (NASDAQ: KROS) is now covered by analysts at Guggenheim. They set a "buy" rating and a $96.00 price target on the stock.
Low
Report
Keros Therapeutics, Inc. (NASDAQ: KROS) is now covered by analysts at Guggenheim. They set a "buy" rating and a $96.00 price target on the stock.
9/23
07:59 am
kros
Keros Therapeutics, Inc. (NASDAQ: KROS) is now covered by analysts at Guggenheim. They set a "buy" rating and a $96.00 price target on the stock.
Low
Report
Keros Therapeutics, Inc. (NASDAQ: KROS) is now covered by analysts at Guggenheim. They set a "buy" rating and a $96.00 price target on the stock.
9/23
05:56 am
kros
Rating for KROS
Low
Report
Rating for KROS
9/23
05:56 am
kros
Rating for KROS
Low
Report
Rating for KROS